Technology
Health
Biotechnology
IsoRay
$0.37899876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.3789
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0112 (3.05%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell IsoRay and other stocks, options, ETFs, and crypto commission-free!
About
IsoRay, Inc., also called IsoRay, is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Read More Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
Employees
38
Headquarters
Richland, Washington
Founded
1983
Market Cap
25.51M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
585.76K
High Today
$0.38
Low Today
$0.365
Open Price
$0.3752
Volume
20.29K
52 Week High
$1.22
52 Week Low
$0.2691
Collections
Technology
Health
Biotechnology
Medical
Cancer Prevention
US
North America
Female CEOs
News
MarketBeatMar 4
Stock Price, News, & Analysis for IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facil...
Price Paid on Robinhood
31% Lower
Right Now
52 Week Low
$0.2691
Average Price Paid
$0.5476
52 Week High
$1.22
Earnings
-$0.04
-$0.03
-$0.01
$0.00
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected May 2, After Hours